Welcome to our dedicated page for Enanta Pharmaceuticals SEC filings (Ticker: ENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Enanta Pharmaceuticals disclosures often feels like parsing a medical journal: hundreds of pages of virology data, clinical endpoints and royalty formulas. If you have ever wondered, “How do I find Enanta Pharmaceuticals insider trading Form 4 transactions before a trial read-out?� or “Where is the cash-runway detail buried in the latest Enanta Pharmaceuticals quarterly earnings report 10-Q filing?�, you are not alone.
Stock Titan solves that problem. Our AI reviews every 10-K, 10-Q, 8-K and proxy statement the moment it hits EDGAR, then generates plain-English summaries and red-flag alerts. Need pipeline context? The AI-powered summaries highlight RSV Phase II milestones straight inside the Enanta Pharmaceuticals annual report 10-K simplified. Tracking insider sentiment? Receive real-time notifications for Enanta Pharmaceuticals Form 4 insider transactions real-time, complete with easy charts of executive stock transactions Form 4. Curious about sudden stock moves? An 8-K material events explained card outlines trial results and AbbVie royalty updates in minutes, not hours.
Whether you’re comparing R&D spend across quarters, scanning the proxy for Enanta Pharmaceuticals executive compensation, or seeking an earnings report filing analysis, our platform keeps research focused and efficient. Investors use these insights to:
- Monitor cash usage versus upcoming clinical catalysts
- Track management’s share purchases or sales for sentiment clues
- Understand revenue recognition from AbbVie collaborations without wading through footnotes
Scott T. Rottinghaus, identified in this filing as Chief Medical Officer of Enanta Pharmaceuticals (ENTA), reported a non-sale equity transaction dated 08/08/2025 in which 2,217 shares of ENTA common stock were forfeited to satisfy withholding taxes arising from the settlement of a portion of a restricted stock unit award granted on August 8, 2022. The filing lists a per-share amount of $6.99 associated with the transaction. Following the withholding forfeiture, the reporting person beneficially owns 22,590 shares of common stock directly. The Form 4 entry indicates this was an internal tax-withholding action rather than an open-market disposition and was executed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
